Overview of the 2012 Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting on the Edwards SAPIEN transcatheter heart valve for high-risk aortic stenosis patients - 26/04/13
Résumé |
The Edwards SAPIEN transcatheter heart valve (THV) is approved for aortic stenosis patients considered inoperable because of high surgical risk. Based on the high-risk arm of the PARTNER trial, the Food and Drug Administration's Circulatory System Devices Panel reviewed an additional indication for use in high-risk, operable patients. Although several concerns were raised regarding safety, trial misconduct, and several subgroup analyses, most panel members agreed that the Edwards SAPIEN THV (Edwards Lifesciences LLC, Irvine, CA), when used in high-risk patients, is noninferior to surgical aortic valve replacement. The panel voted 11 to 0 (with 1 abstention) that the benefits of the Edwards SAPIEN THV do outweigh the risks for use in the indicated patient population. This summary aims to describe the discussions and recommendations made during the meeting. Based on the panel recommendation, the device was approved by the Food and Drug Administration.
Le texte complet de cet article est disponible en PDF.Plan
Vol 165 - N° 5
P. 710-715 - mai 2013 Retour au numéro
Article précédent
- Rationale and design of the LEADERS FREE trial: A randomized double-blind comparison of the BioFreedom drug-coated stent vs the Gazelle bare metal stent in patients at high bleeding risk using a short (1 month) course of dual antiplatelet therapy
- Philip Urban, Alex Abizaid, Bernard Chevalier, Samantha Greene, Ian Meredith, Marie-Claude Morice, Stuart Pocock
- Sensitive troponin assays and N-terminal pro–B-type natriuretic peptide in acute coronary syndrome: Prediction of significant coronary lesions and long-term prognosis
- Jørgen Gravning, Marit Kristine Smedsrud, Torbjørn Omland, Christian Eek, Helge Skulstad, Lars Aaberge, Bjørn Bendz, John Kjekshus, Lars Mørkrid, Thor Edvardsen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?